Amgen (AMGN) PT Raised to $190 at BMO Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/8/2026
Go back to Amgen (AMGN) PT Raised to $190 at BMO Capital
July 28, 2016 7:18 AM EDT
Leerink Partners reiterated a Market Perform rating on Amgen (NASDAQ: AMGN), and raised the price target to $201.00 (from $186.00), following the company's 2Q earnings report. AMGN reported total revenues of $5.69bn, beating consensus by 3%. The company also reported an operating margin of 51% on expenses of $2.876bn, which was in-line with consensus.
Analyst Geoffrey C. Porges commented, "Amgen Reported Q2 Results Beating Consensus for Revenue by 2% and Beating by 3% on EPS. Total revenue of $5.69bn included $5.474bn in product sales that beat consensus by 3% and missed our estimate by -2%. As with the... More
July 27, 2016 4:02 PM EDT
Amgen (NASDAQ: AMGN) reported Q2 EPS of $2.84, $0.10 better than the analyst estimate of $2.74. Revenue for the quarter came in at $5.69 billion versus the consensus estimate of $5.58 billion.
GUIDANCE:
Amgen sees FY2016 EPS of $11.10-$11.40. Amgen sees FY2016 revenue of... More
